Advicenne S.A. (ALDVI.PA)
EUR 1.62
(-1.1%)
EUR 1.62
(-1.1%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 12.17 Million EUR | 16.7% |
| 2022 | 10.43 Million EUR | 7197.28% |
| 2021 | -147 Thousand EUR | 95.06% |
| 2020 | -2.97 Million EUR | 78.7% |
| 2019 | -13.95 Million EUR | 45.94% |
| 2018 | -25.81 Million EUR | 27.25% |
| 2017 | -35.48 Million EUR | -2146.23% |
| 2016 | 1.73 Million EUR | -1.59% |
| 2015 | 1.76 Million EUR | 243.49% |
| 2014 | -1.22 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 15.83 Million EUR | 30.08% |
| 2024 Q2 | 15.83 Million EUR | 0.0% |
| 2023 Q1 | 15.19 Million EUR | 45.67% |
| 2023 FY | 12.17 Million EUR | 16.7% |
| 2023 Q4 | 12.17 Million EUR | -1.35% |
| 2023 Q3 | 12.34 Million EUR | -19.41% |
| 2023 Q2 | 15.31 Million EUR | 0.76% |
| 2022 FY | 10.43 Million EUR | 7197.28% |
| 2022 Q4 | 10.43 Million EUR | 1.16% |
| 2022 Q3 | 10.31 Million EUR | 71.23% |
| 2022 Q2 | 6.02 Million EUR | 2.02% |
| 2022 Q1 | 5.9 Million EUR | 4116.33% |
| 2021 Q3 | -212 Thousand EUR | 92.69% |
| 2021 Q1 | -2.62 Million EUR | 11.71% |
| 2021 FY | -147 Thousand EUR | 95.06% |
| 2021 Q4 | -147 Thousand EUR | 30.66% |
| 2021 Q2 | -2.9 Million EUR | -10.48% |
| 2020 FY | -2.97 Million EUR | 78.7% |
| 2020 Q4 | -2.97 Million EUR | 4.53% |
| 2020 Q1 | -8.89 Million EUR | 36.26% |
| 2020 Q2 | -8.74 Million EUR | 1.69% |
| 2020 Q3 | -3.11 Million EUR | 64.39% |
| 2019 FY | -13.95 Million EUR | 45.94% |
| 2019 Q2 | -20.33 Million EUR | 0.41% |
| 2019 Q1 | -20.42 Million EUR | 20.89% |
| 2019 Q4 | -13.95 Million EUR | 8.04% |
| 2019 Q3 | -15.17 Million EUR | 25.37% |
| 2018 Q4 | -25.81 Million EUR | 0.0% |
| 2018 FY | -25.81 Million EUR | 27.25% |
| 2018 Q3 | -25.81 Million EUR | 20.48% |
| 2018 Q2 | -32.45 Million EUR | 0.0% |
| 2018 Q1 | -32.45 Million EUR | 8.52% |
| 2017 Q2 | -13.73 Million EUR | -0.56% |
| 2017 Q3 | -35.48 Million EUR | -158.25% |
| 2017 Q4 | -35.48 Million EUR | -0.0% |
| 2017 FY | -35.48 Million EUR | -2146.23% |
| 2017 Q1 | -13.66 Million EUR | -887.95% |
| 2016 Q3 | 2.2 Million EUR | 0.0% |
| 2016 Q1 | 1.63 Million EUR | 0.0% |
| 2016 Q4 | 1.73 Million EUR | -21.22% |
| 2016 FY | 1.73 Million EUR | -1.59% |
| 2015 FY | 1.76 Million EUR | 243.49% |
| 2014 FY | -1.22 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | 1805.182% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 106.197% |
| Adocia SA | 127 Thousand EUR | -9486.614% |
| Aelis Farma SA | -16.19 Million EUR | 175.191% |
| Biophytis S.A. | 2.7 Million EUR | -350.425% |
| genOway Société anonyme | 2.97 Million EUR | -309.523% |
| IntegraGen SA | -709.74 Thousand EUR | 1815.395% |
| Medesis Pharma S.A. | 1.15 Million EUR | -951.191% |
| Neovacs S.A. | -237.08 Thousand EUR | 5235.246% |
| NFL Biosciences SA | -2.27 Million EUR | 634.96% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -179.467% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | 1565.9% |
| Sensorion SA | 1.37 Million EUR | -783.385% |
| Theranexus Société Anonyme | 2.44 Million EUR | -398.127% |
| TME Pharma N.V. | -1.07 Million EUR | 1228.36% |
| Valbiotis SA | -18.13 Million EUR | 167.121% |
| TheraVet SA | 12.78 Thousand EUR | -95128.784% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | -458.486% |
| DBV Technologies S.A. | -114.95 Million USD | 110.591% |
| Genfit S.A. | -7.61 Million EUR | 259.966% |
| GeNeuro SA | 5.91 Million EUR | -105.993% |
| Innate Pharma S.A. | -30.71 Million EUR | 139.642% |
| Inventiva S.A. | 10.48 Million EUR | -16.074% |
| MaaT Pharma SA | -10.2 Million EUR | 219.304% |
| MedinCell S.A. | 39.5 Million EUR | 69.178% |
| Nanobiotix S.A. | -24.71 Million EUR | 149.256% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 55.122% |
| Poxel S.A. | 44.55 Million EUR | 72.677% |
| GenSight Biologics S.A. | 16.29 Million EUR | 25.279% |
| Transgene SA | -14.4 Million EUR | 184.496% |
| Valneva SE | 82.73 Million EUR | 85.285% |